rilogrotug

Home
Ligands
rilogrotug

GtoPdb Ligand ID: 13664

Synonyms: AV380

Comment: Rilogrotug (AV-380; AVEO Pharmaceuticals) is a humanized anti-growth differentiation factor 15 (GDF15) IgG1κ monoclonal antibody. Blocking GDF15 binding to its receptor GFRAL is recognised to induce anti-cachexia efficacy in preclinical models and is proposed as a therapeutic modality to treat cachexia that is caused by over-expression of GDF15 (e.g. cancer-associated cachexia) [1,3].

Data in support of clinical efficacy from a phase 2 trial in patients with cancer-associated cachexia who were administered Pfizer's anti-GDF15 monoclonal, ponsegromab, were published in late 2024 [2].

Bioactivity Comments
Peptide sequence analysis indicates exact matches between the INN-provided heavy and light chain sequences for rilogrotug and the sequences claimed in patent WO2014100689A1 for the antibody referred to as Hu01G06 IGKV1-39 F1 therein [4]. Binding affinity data presented in this patent provides a K_D of 66 pM for Hu01G06 IGKV1-39 F1 binding to recombinant human GDF15.

Bioactivity Comments

Peptide sequence analysis indicates exact matches between the INN-provided heavy and light chain sequences for rilogrotug and the sequences claimed in patent WO2014100689A1 for the antibody referred to as Hu01G06 IGKV1-39 F1 therein [4]. Binding affinity data presented in this patent provides a K_D of 66 pM for Hu01G06 IGKV1-39 F1 binding to recombinant human GDF15.